What are COVID-19 antibodies, is there a certain level needed for protection, and how well do COVID-19 vaccines work in people with cancer? In this Q&A, NCI experts discuss emerging research findings from the SeroNet program that are shedding light on these and other important questions.
How the Coronavirus Affects People With Mesothelioma
Antibodies and Vaccines as Drugs for COVID-19, keystone symposia
Antiviral drug discovery: preparing for the next pandemic - Chemical Society Reviews (RSC Publishing) DOI:10.1039/D0CS01118E
Lowy: “Our patients are counting on us, and we must not let them down” NCI Frederick lab takes aim at Covid-19 - The Cancer Letter
UAMS Researchers Awarded $1.3 Million to Conduct SARS-CoV-2 Serological Study in Arkansas
Recent Advancement of Nanostructured Materials for Clinical Challenges in Vaccinology
Antibodies and Vaccines as Drugs for COVID-19, keystone symposia
NCI's Research on COVID-19, Vaccines, and Antibodies - NCI
g201503261017016651133.jpg
Multimedia National Institutes of Health (NIH)
Adjuvants enhance vaccine immunogenicity. (a) Nonadjuvanted subunit
YearofCOVID: Retooling Research to Fight a Pandemic
Frontiers Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants
